Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
27
MBIO Quote, Financials, Valuation and Earnings
Last price:
$0.16
Seasonality move
:
-6.07%
Day range:
$0.16 - $0.17
52-week range:
$0.13 - $1.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
376.9K
Avg. volume:
678.3K
1-year change:
-86.19%
Market cap:
$8M
Revenue:
--
EPS (TTM):
-$1.56
Analysts' Opinion
-
Consensus RatingMustang Bio has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.50, Mustang Bio has an estimated upside of 1096.89% from its current price of $0.17.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $0.17.
Fair Value
-
According to the consensus of 1 analyst, Mustang Bio has 1096.89% upside to fair value with a price target of $17.50 per share.
MBIO vs. S&P 500
-
Over the past 5 trading days, Mustang Bio has underperformed the S&P 500 by -8.3% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Mustang Bio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Mustang Bio has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Mustang Bio reported revenues of --.
Earnings Growth
-
Mustang Bio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Mustang Bio reported earnings per share of -$0.04.
Enterprise value:
4.5M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$76.8M | -$61.3M | -$21.4M | -$11.7M | -$1.5M | |
| EBITDA | -$72.8M | -$57.4M | -$22.3M | -$9.7M | -$1.4M | |
| Diluted EPS | -$10.93 | -$7.77 | -$1.56 | -$1.23 | -$0.04 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $75.6M | $121.9M | $94.4M | $13.6M | $6.1M | |
| Total Assets | $86.1M | $134.7M | $108.8M | $20.6M | $7.2M | |
| Current Liabilities | $7.6M | $10.5M | $13.6M | $14.2M | $15M | |
| Total Liabilities | $9.7M | $12.5M | $44.5M | $16.6M | $15.8M | |
| Total Equity | $76.4M | $122.2M | $64.3M | $4M | -$8.7M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$64.5M | -$57.5M | -$16.7M | -$12M | -$1.8M | |
| Cash From Investing | -$4M | $5.5M | -$30K | $6M | -- | |
| Cash From Financing | $39M | -$30M | $10.3M | $250K | $1M | |
| Free Cash Flow | -$68.6M | -$58M | -$16.7M | -$12.1M | -$1.8M | |
MBIO
Sector
Market Cap
$8M
$46.1M
Price % of 52-Week High
10.92%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-86.19%
-30.52%
Beta (5-Year)
1.806
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$0.17
200-day SMA
Sell
Level
$0.36
Bollinger Bands (100)
Sell
Level
0.19 - 0.31
Chaikin Money Flow
Sell
Level
-485.9M
20-day SMA
Sell
Level
$0.19
Relative Strength Index (RSI14)
Sell
Level
34.13
ADX Line
Sell
Level
21.41
Williams %R
Neutral
Level
-75.6007
50-day SMA
Sell
Level
$0.22
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
255M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Stock Forecast FAQ
In the current month, MBIO has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The MBIO average analyst price target in the past 3 months is $17.50.
-
Where Will Mustang Bio Stock Be In 1 Year?
According to analysts, the consensus estimate is that Mustang Bio share price will rise to $17.50 per share over the next 12 months.
-
What Do Analysts Say About Mustang Bio?
Analysts are divided on their view about Mustang Bio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Mustang Bio is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Mustang Bio's Price Target?
The price target for Mustang Bio over the next 1-year time period is forecast to be $17.50 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is MBIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Mustang Bio is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of MBIO?
You can purchase shares of Mustang Bio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Mustang Bio shares.
-
What Is The Mustang Bio Share Price Today?
Mustang Bio was last trading at $0.16 per share. This represents the most recent stock quote for Mustang Bio. Yesterday, Mustang Bio closed at $0.17 per share.
-
How To Buy Mustang Bio Stock Online?
In order to purchase Mustang Bio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
